Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 5Gastrointestinal Stromal Tumors 5Recurrence 4Mastocytosis, Systemic 4Sarcoma 2Neoplasm Metastasis 2Leukemia, Mast-Cell 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Core Binding Factor Acute Myeloid Leukemia 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Recurrence × avapritinib × Clear all
NCT04773782 2026-01-13

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Blueprint Medicines Corporation

Phase 1/2 Completed
29 enrolled
CNS

Glioma, Recurrence, Central Nervous System Neoplasms

NCT04908176 2024-12-13

A Drug-drug Interaction Study of Avapritinib and Midazolam

Blueprint Medicines Corporation

Phase 1 Completed
10 enrolled
CNSGastrointestinalSarcoma

Glioblastoma, Neoplasms, Recurrence, Gastrointestinal Stromal Tumors

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Children's Hospital of Soochow University

Phase 2 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02561988 2023-03-17

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Blueprint Medicines Corporation

Phase 1 Completed
86 enrolled 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Recurrence, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡